Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to treat genetically defined diseases. Its lead candidate, losmapimod, is being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating muscle disorder. Fulcrum’s growth is driven by advancing clinical trials, expanding its drug pipeline, and the growing interest in precision medicine targeting genetic conditions.
On the chart, a confirmation bar with rising volume indicates strong buying interest. The price has entered the momentum zone by moving above the .236 Fibonacci level. A trailing stop can be placed just below this level using the Fibonacci snap tool to protect profits while leaving room for further gains.
On the chart, a confirmation bar with rising volume indicates strong buying interest. The price has entered the momentum zone by moving above the .236 Fibonacci level. A trailing stop can be placed just below this level using the Fibonacci snap tool to protect profits while leaving room for further gains.
Read on substack
link.traderspro.com/k2r16ljr
Join Discord Server
link.traderspro.com/gvm0e9df
Learn this trading method
link.traderspro.com/f39nzb0t
Daily email newsletter
link.traderspro.com/kuPneCQK
link.traderspro.com/k2r16ljr
Join Discord Server
link.traderspro.com/gvm0e9df
Learn this trading method
link.traderspro.com/f39nzb0t
Daily email newsletter
link.traderspro.com/kuPneCQK
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Read on substack
link.traderspro.com/k2r16ljr
Join Discord Server
link.traderspro.com/gvm0e9df
Learn this trading method
link.traderspro.com/f39nzb0t
Daily email newsletter
link.traderspro.com/kuPneCQK
link.traderspro.com/k2r16ljr
Join Discord Server
link.traderspro.com/gvm0e9df
Learn this trading method
link.traderspro.com/f39nzb0t
Daily email newsletter
link.traderspro.com/kuPneCQK
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.